You are here

  • Home
  • Archive
  • Volume 78, Issue 10
  • Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

Citation Tools

Article menu

Download PDFPDF

Rheumatoid arthritis
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Takeuchi T, Tanaka Y, Tanaka S, et al
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Annals of the Rheumatic Diseases 2019;78:1305-1319.